2017
Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study
Hogg RS, Eyawo O, Collins AB, Zhang W, Jabbari S, Hull MW, Lima VD, Ahmed T, Kendall CE, Althoff KN, Justice AC, Barrios R, Shoveller J, Montaner JSG, study C. Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study. The Lancet HIV 2017, 4: e270-e276. PMID: 28262574, PMCID: PMC5761654, DOI: 10.1016/s2352-3018(17)30029-2.Peer-Reviewed Original ResearchConceptsHealth-adjusted life expectancyActive antiretroviral therapySelect comorbiditiesHIV statusLife expectancyGeneral populationPopulation-based observational cohort studyShorter overall life expectancyHIV-negative counterpartsCase-finding algorithmHIV-negative menHIV-negative populationObservational cohort studyComplex care needsService delivery interventionsAge 20 yearsYears of ageCauses of comorbidityShort life expectancyOverall life expectancyHealthy stateElectronic health recordsAntiretroviral therapyCohort studyRetrospective cohort
2015
Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy
Viswanathan S, Justice AC, Alexander GC, Brown TT, Gandhi NR, McNicholl IR, Rimland D, Rodriguez-Barradas MC, Jacobson LP. Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 493-498. PMID: 25886923, PMCID: PMC4482798, DOI: 10.1097/qai.0000000000000643.Peer-Reviewed Original ResearchConceptsHIV RNA suppressionOdds of suppressionActive antiretroviral therapyRNA suppressionHAART regimenAntiretroviral therapyVeterans Aging Cohort Study Virtual CohortHighly Active Antiretroviral TherapyFirst HAART regimenProtease inhibitor usersRepeated-measures logistic regressionVeterans' Affairs pharmacyViral load suppressionHAART usersNew HAARTRegimen typeInhibitor usersHIV infectionNonnucleoside reverseLow adherenceAdherence levelsPerfect adherenceVirtual cohortLogistic regressionDuration of time
2014
The VACS Index Predicts Mortality in a Young, Healthy HIV Population Starting Highly Active Antiretroviral Therapy
Bebu I, Tate J, Rimland D, Mesner O, Macalino GE, Ganesan A, Okulicz JF, Bavaro M, Weintrob AC, Justice AC, Agan BK. The VACS Index Predicts Mortality in a Young, Healthy HIV Population Starting Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2014, 65: 226-230. PMID: 24226058, PMCID: PMC4091811, DOI: 10.1097/qai.0000000000000045.Peer-Reviewed Original ResearchConceptsVACS IndexActive antiretroviral therapyCause mortalityAntiretroviral therapyHIV populationVeterans Aging Cohort Study (VACS) IndexActive antiretroviral therapy (HAART) initiationAntiretroviral therapy initiationPrediction of mortalityGood discriminationNHS subjectsTherapy initiationDifferent time pointsStudy cohortSimilar patientsClinical variablesEarly risk assessmentMedical historyVAC indexHealthy populationMortalityStudy indicesOutcome predictionTime pointsLaboratory data
2012
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.
Althoff KN, Buchacz K, Hall HI, Zhang J, Hanna DB, Rebeiro P, Gange SJ, Moore RD, Kitahata MM, Gebo KA, Martin J, Justice AC, Horberg MA, Hogg RS, Sterling TR, Cescon A, Klein MB, Thorne JE, Crane HM, Mugavero MJ, Napravnik S, Kirk GD, Jacobson LP, Brooks JT. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Annals Of Internal Medicine 2012, 157: 325-35. PMID: 22944874, PMCID: PMC3534765, DOI: 10.7326/0003-4819-157-5-201209040-00005.Peer-Reviewed Original ResearchConceptsCD4 cell countCD4 T-lymphocyte cell countMedian CD4 cell countT-lymphocyte cell countAntiretroviral therapy useHIV VLCell countNA-ACCORDHIV RNATherapy useViral loadU.S. National HIV/AIDS StrategyHealth outcomesNational HIV/AIDS StrategyCanadian HIV Trials NetworkHIV/AIDS StrategyActive antiretroviral therapyHIV outpatient clinicAnnual cross-sectional analysesHIV Cohort StudyProportion of participantsNational surveillance systemRelated health outcomesSimilar demographic characteristicsCross-sectional analysis
2009
HIV infection in the elderly
Gebo KA, Justice A. HIV infection in the elderly. Current Infectious Disease Reports 2009, 11: 246-254. PMID: 19366568, PMCID: PMC3129647, DOI: 10.1007/s11908-009-0036-0.Peer-Reviewed Original ResearchOlder patientsYounger patientsBetter virologic suppressionOlder HIV patientsActive antiretroviral therapyManagement of HIVPrevalence of HIVDrug-drug interactionsAntiretroviral regimenHAART initiationHAART regimenVirologic suppressionAntiretroviral therapyHIV patientsImmunologic benefitsHIV infectionPatientsSide effectsHIVPopulation agesRegimenAgeHAARTComorbiditiesTherapy
2008
Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies
Harris RJ, Sterne J, Abgrall S, Dabis F, Reiss P, Saag M, Phillips AN, Chêne G, Gill JM, Justice AC, Rockstroh J, Sabin CA, Mocroft A, Bucher HC, Hogg RS, Monforte AD, May M, Egger M. Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies. Antiviral Therapy 2008, 13: 959-967. PMID: 19195321, PMCID: PMC4507810, DOI: 10.1177/135965350801300802.Peer-Reviewed Original ResearchConceptsHIV type-1-infected patientsMild anemiaAntiretroviral therapyHemoglobin levelsAdjusted hazard ratioMonths of HAARTStart of HAARTActive antiretroviral therapyT-cell countsPrevalence of anemiaProspective cohort studyLong-term prognosisBaseline anemiaAIDS eventsHazard ratioCohort studyPrognostic importancePrognostic valueProspective studyUntreated individualsPatientsAnemiaHigh mortalityHAARTNormal hemoglobin
2006
Increased COPD Among HIV-Positive Compared to HIV-Negative Veterans
Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, Justice AC, Team F. Increased COPD Among HIV-Positive Compared to HIV-Negative Veterans. CHEST Journal 2006, 130: 1326-1333. PMID: 17099007, DOI: 10.1378/chest.130.5.1326.Peer-Reviewed Original ResearchConceptsInjection drug usePrevalence of COPDHIV-negative subjectsIndependent risk factorHIV infectionICD-9 codesRisk factorsDiagnostic codesAlcohol abuseICD-9 diagnostic codesHIV-negative veteransActive antiretroviral therapyHIV-positive patientsEra of HAARTHIV-negative menHIV-positive subjectsProspective observational studyPathogenesis of COPDRisk of COPDHealth care providersElectronic medical recordsRace/ethnicityAntiretroviral therapyHIV-positiveCigarette smokingHIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis
May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fätkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. The Lancet 2006, 368: 451-458. PMID: 16890831, DOI: 10.1016/s0140-6736(06)69152-6.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyCD4 cell countAntiretroviral therapyHazard ratioTreatment responseTreatment-naive HIV-1-infected adultsCell countHIV-1-infected adultsMedian CD4 cell countHIV-1 RNA copiesCharacteristics of patientsHIV-1 RNAShort-term prognosisHIV treatment responseProportion of womenPrimary endpointVirological responseCohort studyHIV infectionCox regressionHAARTPatientsRNA copiesCorresponding figurePrognosis
2005
Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America
Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P, Kirk O, Bernasconi E, Grabar S, Justice A, Staszewski S, Fätkenheuer G, Sterne JA. Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America. Clinical Infectious Diseases 2005, 41: 1772-1782. PMID: 16288403, DOI: 10.1086/498315.Peer-Reviewed Original ResearchConceptsIncidence of tuberculosisMonths of HAARTMultivariable analysisMultivariable Poisson regression modelsInitiation of HAARTLevel of immunodeficiencyLower baseline CD4Active antiretroviral therapyHIV RNA levelsRisk of tuberculosisInjection drug usersMode of transmissionPoisson regression modelsBaseline CD4HAART initiationHigher CD4Antiretroviral therapyTB epidemicIncidence rateCopies/HAARTDrug usersPatientsTuberculosisCD4The Impact of Cigarette Smoking on Mortality, Quality of Life, and Comorbid Illness Among HIV‐Positive Veterans
Crothers K, Griffith TA, McGinnis KA, Rodriguez‐Barradas M, Leaf DA, Weissman S, Gibert CL, Butt AA, Justice AC. The Impact of Cigarette Smoking on Mortality, Quality of Life, and Comorbid Illness Among HIV‐Positive Veterans. Journal Of General Internal Medicine 2005, 20: 1142-1145. PMID: 16423106, PMCID: PMC1490270, DOI: 10.1111/j.1525-1497.2005.0255.x.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseQuality of lifeHIV-positive patientsImpact of smokingPhysical component summaryHIV-positive veteransCurrent smokersRespiratory symptomsBacterial pneumoniaActive antiretroviral therapyCD4 cell countHIV RNA levelsProspective observational studyObstructive pulmonary diseaseShort Form-12National VA databasesRace/ethnicityAntiretroviral therapyComorbid illnessesComponent summaryHIV infectionPatient questionnairePulmonary diseaseChart extractionCigarette smokingDifferences between Infectious Diseases—Certified Physicians and General Medicine—Certified Physicians in the Level of Comfort with Providing Primary Care to Patients
Fultz SL, Goulet JL, Weissman S, Rimland D, Leaf D, Gibert C, Rodriguez-Barradas MC, Justice AC. Differences between Infectious Diseases—Certified Physicians and General Medicine—Certified Physicians in the Level of Comfort with Providing Primary Care to Patients. Clinical Infectious Diseases 2005, 41: 738-743. PMID: 16080098, DOI: 10.1086/432621.Peer-Reviewed Original ResearchConceptsID clinicComorbid conditionsActive antiretroviral therapyInfectious disease clinicCommon comorbid conditionsHuman immunodeficiency virusGeneral medical clinicLevel of comfortAntiretroviral therapyComorbid diseasesDisease clinicSuch patientsSelf-reported comfortImmunodeficiency virusPrimary careHIV medicinePrescribing medicationsSubstantial prevalencePatientsPhysician levelClinicMedical clinicsGeneralist physiciansHypertensionHyperlipidemiaThe Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy
d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, Reiss P, Egger M. The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy. JAMA Internal Medicine 2005, 165: 416-423. PMID: 15738371, DOI: 10.1001/archinte.165.4.416.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyAIDS eventsAntiretroviral therapyViral etiologyRate of declineAntiretroviral-naive individualsRates of AIDSIncidence of AIDSCohort CollaborationCD4 countMonths 0Different etiologiesFungal etiologyChanging IncidenceHAARTPoisson regressionEtiologyIncidenceRNA levelsAIDSViral eventsTherapyMonths
2004
Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy
Raffanti SP, Fusco JS, Sherrill BH, Hansen NI, Justice AC, D’Aquila R, Mangialardi WJ, Fusco GP. Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2004, 37: 1147-1154. PMID: 15319674, DOI: 10.1097/01.qai.0000136738.24090.d0.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCopies/mLBaseline HIV-1 RNA levelsNew AIDSCopies/Moderate viremiaRNA levelsPlasma HIV-1 RNAAIDS-defining diagnosisAntiretroviral therapy historyActive antiretroviral therapyUnited States cohortHIV-1 RNACells/Proportional hazards modelCD4 count changesImmunologic deteriorationAntiretroviral therapyCD4 countPrior AIDSUndetectable viremiaViral suppressionImmunologic statusHIV infectionClinical benefitRisk of diabetes in HIV infected veterans pre‐ and post‐HAART and the role of HCV coinfection
Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC. Risk of diabetes in HIV infected veterans pre‐ and post‐HAART and the role of HCV coinfection. Hepatology 2004, 40: 115-119. PMID: 15239093, DOI: 10.1002/hep.20289.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusPre-HAART eraHAART eraRisk of diabetesHCV coinfectionHCV infectionHigh riskHepatitis C virus infectionMultivariate Cox regression analysisVeterans Affairs administrative databasesActive antiretroviral therapyC virus infectionCox regression analysisIncidence of diabetesKaplan-Meier curvesCox regression methodsDiagnosis of diabetesHCV-HIVAntiretroviral therapyHazard ratioLiver diseaseImmunodeficiency virusAdministrative databasesVirus infectionDrug diagnoses
2003
Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era
King JT, Justice AC, Roberts MS, Chang CC, Fusco JS. Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era. Medical Decision Making 2003, 23: 9-20. PMID: 12583451, DOI: 10.1177/0272989x02239652.Peer-Reviewed Original ResearchConceptsCells/mm3Long-term survivalCD4 cell countAge-associated mortalityTreatment failureHIV/AIDSUS life tablesCell countActive antiretroviral therapy (HAART) eraBaseline CD4 cell countHIV/AIDS patientsLong-term survival dataShort-term survival dataAntiretroviral therapy eraPre-HAART cohortTreatment mortality rateActive antiretroviral therapyTreatment failure rateRisk of mortalitySurvival dataShort-term survivalHAART failureTherapy eraAntiretroviral therapyObservational cohort
2002
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne J, Collaboration T. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. The Lancet 2002, 360: 119-129. PMID: 12126821, DOI: 10.1016/s0140-6736(02)09411-4.Peer-Reviewed Original ResearchConceptsCells/microLCD4 cell countBaseline CD4 cell countActive antiretroviral therapyProbability of progressionCell countAntiretroviral therapyCohort studyBaseline HIV-1 viral loadCD4 cells/microLCD4 cells/microL.HIV-1 viral loadHIV-1-infected patientsART Cohort CollaborationTreatment-naive patientsCells/microL.Dominant prognostic factorFuture treatment guidelinesInjection drug useHigh-risk stratumLow-risk stratumSingle cohort studyCohort CollaborationNew AIDSAdult patients